731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)

BACKGROUND: Carbapenem-resistant Enterobacterales and multidrug resistant Pseudomonas aeruginosa are global antimicrobial resistance threats. Cefepime-taniborbactam (FTB) is an investigational β-lactam/ β-lactamase inhibitor combination that is active against Enterobacterales and Pseudomonas aerugin...

Descripción completa

Detalles Bibliográficos
Autores principales: McGovern, Paul C, Wagenlehner, Florian, Gasink, Leanne, Moeck, Greg, McLeroth, Patrick L, Beth, Mary, Dane, Aaron, Henkel, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752361/
http://dx.doi.org/10.1093/ofid/ofac492.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752361/
http://dx.doi.org/10.1093/ofid/ofac492.022

Ejemplares similares